Video

CRC Safety Lead-in: ASCO GI 2019 Updates

Scott Kopetz, MD, PhD, FACP; Ryan Corcoran, MD, PhD; review the design and updated safety lead-in data from the BEACON study looking at the triplet regimen of encorafenib, binimetinib, and cetuximab, a regimen also tested in the ANCHOR trial.

Related Videos
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University
Kimmie Ng, MD, MPH
Piotr Rutkowski, MD
Yelena Y. Janjigian, MD
Zhi Peng, MD
Josep Llovet, MD
Cathy Eng, MD, FACP, FASCO
Kimmie Ng, MD, MPH
Ruihua Xu, MD, PhD, professor, medical oncology, Department of Medical Oncology, president, Sun Yat-sen University Cancer Center, chairman, Chinese Society of Clinical Oncology
Kimmie Ng, MD, MPH
Related Content
John H. Strickler, MD
October 23rd 2024

Telisotuzumab Adizutecan Delivers Early Signals of Antitumor Activity in CRC

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

John H. Strickler, MD
October 21st 2024

Telisotuzumab Adizutecan Represents a Novel c-Met–Targeting ADC in MET-Amplified CRC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

The OncFive
October 19th 2024

The OncFive: Top Oncology News and Trends for the Week of 10/13

FDA
October 18th 2024

FDA Approves Zolbetuximab Plus Chemo for CLDN18.2+ Gastric or GEJ Adenocarcinoma